Workshop highlights include:

  • Discussing the growing need for novel ADC payloads in the face of ADC patient resistance mechanisms
  • Weighing up the pros and cons of catalytic and immune-stimulating payloads safety and efficacy 
  • Assessing MoA characterization of ADC payloads beyond classical cytotoxic agentsÂ